NanoViricides' Proposal To Perform Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus Approved By Pillar Committee In Charge In DR Congo
NanoViricides, Inc NNVC
$1.40
▲ +4.48%
(+$0.06)
Open
$1.37
Prev Close
$1.34
Day Range
$1.34 – $1.42
52W Range
$0.85 – $2.23
Market Cap
$32.18M
Beta
1.75
EPS (TTM)
$-0.44
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NYSE MKT LLC |
| Currency | USD |
| IPO Date | 2004-08-12 |
| Shares Out. | 22,780,000 |
| Website | nanoviricides.com/ ↗ |
| Phone | 12039376137 |
NanoViricides, Inc is a publicly traded company under the ticker symbol NNVC on the NYSE MKT LLC, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-06-01)